Medpace: Return Of The Mack, With Double-Digit Revenue Growth

Medpace (NASDAQ:MEDP) delivered a robust Q2 2025 performance, reporting 14% year-over-year revenue growth and an 18.6% increase in EBITDA, significantly surpassing expectations and challenging broader healthcare sector pessimism. The clinical research organization also achieved double-digit net new awards growth and raised its full-year guidance, while demonstrating strong capital allocation by returning $908 million to shareholders through accelerated share buybacks in the first half. Despite a 50% stock rally, Medpace's valuation remains below its five-year average, suggesting potential for further upside if its strong execution persists.

Analysis

Medpace (MEDP) delivered a significantly strong second quarter for 2025, directly challenging the prevailing pessimistic sentiment in the healthcare sector. The company reported 14% year-over-year revenue growth and an 18.6% increase in EBITDA, results that substantially exceeded market expectations. This robust top- and bottom-line performance was complemented by double-digit growth in net new awards, prompting management to raise its full-year guidance. Demonstrating strong conviction in its own valuation and a commitment to shareholder returns, Medpace executed an accelerated share buyback program, returning $908 million to shareholders in the first half of 2025. Despite a notable 50% rally in its stock price, the company's valuation reportedly remains below its 5-year average, suggesting that further appreciation is possible if this high level of operational execution and growth is sustained.

Key Decisions for Investors

• Given the combination of strong fundamental performance and a valuation below its 5-year historical average, investors could view the recent 50% rally as having further upside potential.
• The aggressive $908 million share buyback program in the first half of the year signals strong management confidence and should be considered a key bullish data point in the investment thesis.
• Investors should closely monitor the company's ability to maintain double-digit growth in net new awards, as sustained momentum is critical to justifying a potential re-rating of its valuation multiple.